One of the most persistent barriers in rare disease drug development isn’t the science — it’s identifying and reaching the small number of patients who could benefit from emerging therapies.

Without solving this, even the most promising innovations risk never reaching the people who need them most.

In our latest podcast episode, we explore how the industry can better connect patients to clinical trials — and why this is critical to accelerating progress in rare disease.

We’re delighted to welcome Dr Jennifer Levin, CEO of Medzown, who shares how her team is working to redefine the healthcare ecosystem by improving patient access to advanced therapies and clinical trials across cancer, rare, and complex diseases.

If you’re working in clinical development, patient recruitment, or rare disease, this is a conversation worth your time.